Stoke Therapeutics Rule 144 Notice: 25,000 Shares ($682,750)
Rhea-AI Filing Summary
Stoke Therapeutics (STOK) filed a Rule 144 notice for a proposed sale of 25,000 common shares acquired by an exercise of stock options on 10/08/2025. The shares are to be sold through Morgan Stanley Smith Barney LLC with an aggregate market value of $682,750 against 54,797,418 shares outstanding, indicating the block is a very small portion of the float. The filing shows the option exercise and cash payment both occurred on 10/08/2025, and the seller certifies no undisclosed material nonpublic information.
Related trading history lists 116,472 shares sold in the past three months by the same named insider, generating gross proceeds of $2,532,056.28, executed under a mix of 10b5-1 program and direct sales. These prior disposals and the new Rule 144 notice document routine insider liquidity rather than company operational changes.
Positive
- Exercise funded in cash on 10/08/2025, indicating no seller-side financing
- Brokered through a major firm (Morgan Stanley Smith Barney LLC), supporting orderly execution
- Size is immaterial to float: 25,000 shares is ~0.046 of 54,797,418 outstanding
Negative
- Insider selling activity totaled 116,472 shares in the past three months, raising liquidity questions
- Aggregate insider proceeds of $2,532,056.28 over three months could be perceived negatively by some investors
Insights
TL;DR: Insider exercised options and is selling a small block; recent 3‑month insider sales total $2.53M.
The transaction shows a 10/08/2025 option exercise for 25,000 shares paid in cash and routed to market via Morgan Stanley Smith Barney LLC. The sale size equals 0.046 of outstanding shares, so direct dilution or market impact is likely minimal.
Recent filings show 116,472 shares sold over three months for $2,532,056.28, many executed under a 10b5-1 plan. Watch for additional scheduled 10b5-1 trades or further Form 144 filings over the next 30–90 days as the best near-term indicator of insider liquidity strategy.